iRadimed Corporation Declares Quarterly Dividend of $0.20 (NASDAQ:IRMD)

iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, August 28th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th.

iRadimed has a dividend payout ratio of 40.2% indicating that its dividend is sufficiently covered by earnings.

iRadimed Stock Performance

IRMD traded down $4.35 on Friday, reaching $90.86. 308,080 shares of the company’s stock were exchanged, compared to its average volume of 107,190. iRadimed has a twelve month low of $57.83 and a twelve month high of $107.90. The company’s 50 day moving average is $94.56 and its 200-day moving average is $95.73. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. Sell-side analysts forecast that iRadimed will post 1.52 EPS for the current year.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the sale, the chief executive officer owned 2,175,000 shares in the company, valued at $190,334,250. This trade represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,250 shares of company stock valued at $1,836,403 over the last ninety days. Corporate insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its position in shares of iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 3,307 shares in the last quarter. AQR Capital Management LLC raised its holdings in iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after acquiring an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after acquiring an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.